CCC 2004|
CCC 2004 |
CCS Oral Session: Acute Coronary Syndromes: Prognostic Markers and Pharmacologic Intervention
252 - DOES THE BASELINE ELECTROCARDIOGRAM (ECG) ADD VALUE TO TIME TO TREATMENT IN PREDICTING
SUCCESSFUL REPERFUSION AFTER FIBRINOLYSIS?: INSIGHT FROM ASSENT 3 AND ASSENT 3+
253 - PHYSICAL AND PSYCHOLOGICAL INTERVENTIONS AUGMENT VAGAL MODULATION OF HEART RATE VARIABILITY IN CARDIAC PATIENTS: A META-ANALYSIS
254 - NUMERATORS SEARCHING FOR DENOMINATORS – INSIGHT INTO
PRE-HOSPITAL STEMI CARE: THE PRE-HOSPITAL REPERFUSION GROUP OF EDMONTON [PURGE]
255 - CLINICAL EFFICACY AND TOLERABILITY OF EZETIMIBE
IN HIGH-RISK PATIENTS MANAGED IN A SPECIALTY CARDIOVASCULAR RISK REDUCTION CLINIC
256 - PLATELET TRANSFUSIONS ARE A POTENTIAL CAUSE OF MORTALITY AND MORBIDITY AFTER CORONARY ARTERY BYPASS GRAFTING
257 - FOLIC ACID IMPROVES ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETES; AN EFFECT INDEPENDENT OF HOMOCYSTEINE LOWERING
S Al-Kurtass, Y Fu, G Wagner, S Goodman, CB Granger,
L Wallentin, F Van de Werf, PW Armstrong, for the ASSENT-3 and 3+ Investigators
Edmonton, Alberta; Durham, North Carolina, USA; Leuven, Netherlands
RP Nolan, P Jong, J Stanley, JS Floras, TH Tanaka
Toronto, Ontario
RC Welsh, A Travers, R Williams, M Senaratne, Z Lakhani, PW Armstrong
Edmonton, Alberta
GJ Pearson, GT Gyenes, GA Francis, JS Romney, DM Gilchrist, A Opgenorth
Edmonton, Alberta
ND Desai, V Kapila, MP Pelletier, GN Cohen, BS Goldman, GT Christakis, SE Fremes
Toronto, Ontario
LM Title, E Ur, K Giddens, MJ McQueen, BA Nassar
Halifax, Nova Scotia; Hamilton, Ontario